P2Y₁₂ Inhibitor Monotherapy after Percutaneous Coronary Intervention.

ABSTRACT: In patients with acute and chronic coronary artery disease undergoing percutaneous coronary intervention (PCI), dual antiplatelet therapy (DAPT) has been the cornerstone of pharmacotherapy for the past two decades. Although its antithrombotic benefit is well established, DAPT is associated with an increased risk of bleeding, which is independently associated with poor prognosis. The improvement of the safety profiles of drug-eluting stents has been critical in investigating and implementing shorter DAPT regimens. The introduction into clinical practice of newer generation oral P2Y₁₂ inhibitors such as prasugrel and ticagrelor, which provide more potent and predictable platelet inhibition, has questioned the paradigm of standard DAPT durations after coronary stenting. Over the la

SUBMITTER: Zhou X 

PROVIDER: S-EPMC9604207 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature